Evidence map›Paper›PMID 36425465›Full record

ArticleFrontiers in endocrinology2022

The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort.

Richard Ivell, Kee Heng, Katie Severn, Leen Antonio, Gyorgy Bartfai, Felipe F Casanueva, Ilpo T Huhtaniemi, Aleksander Giwercman, Mario Maggi, Daryl B O'Connor and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. New Insights into the Mechanism of Insulin-like Peptide 3 (International journal of molecular sciences · 2025
    Article
  6. Effects ofAnimal biotechnology · 2025
    Article
  7. Review
  8. Article
  9. INSL3 Variation in Dogs Following Suppression and Recovery of the HPG Axis.Animals : an open access journal from MDPI · 2024
    Article
  10. Biomarkers of aging.Science China. Life sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 8 countries.

Richard IvellSchool of Biosciences, University of Nottingham, Sutton Bonington, United Kingdom.
Kee HengSchool of Biosciences, University of Nottingham, Sutton Bonington, United Kingdom.
Katie SevernSchool of Mathematics, University of Nottingham, Nottingham, United Kingdom.
Leen AntonioDepartment of Chronic Diseases and Metabolism, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
Gyorgy BartfaiDepartment of Obstetrics, Gynaecology and Andrology, Albert Szent-Gyorgy Medical University, Szeged, Hungary.
Felipe F CasanuevaDepartment of Medicine, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (CHUS); CIBER de Fisiopatología Obesidad y Nutricion (CB06/03), Instituto Salud Carlos III, Santiago de Compostela, Spain.
Ilpo T HuhtaniemiInstitute of Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Aleksander GiwercmanDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Mario MaggiAndrology Unit, "Mario Serio" Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Daryl B O'ConnorSchool of Psychology, University of Leeds, Leeds, United Kingdom.
Terence W O'NeillCentre for Epidemiology Versus Arthritis, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Margus PunabAndrology Clinic, Tartu University Hospital; and Institute of Clinical Medicine, and Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Giulia RastrelliAndrology Unit, "Mario Serio" Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Jolanta Slowikowska-HilczerDepartment of Andrology and Reproductive Endocrinology, Medical University of Łódź, Łódź, Poland.
Jos TournoyDepartment of Geriatrics, University Hospitals Leuven, and Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Dirk VanderschuerenDepartment of Chronic Diseases and Metabolism, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
Frederick C W WuDepartment of Endocrinology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Ravinder Anand-IvellSchool of Biosciences, University of Nottingham, Sutton Bonington, United Kingdom.
University of Nottingham · GBKU Leuven · BEUniversity of Florence · ITComplejo Hospitalario Universitario de Santiago · ESImperial College London · GBLund University · SEManchester University NHS Foundation Trust · GBMedical University of Lodz · PLUniversity of Leeds · GBUniversity of Szeged · HUUniversity of Tartu · EEVersus Arthritis · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Insulin-like peptide 3 (INSL3) is a constitutive hormone secreted in men by the mature Leydig cells of the testes. It is an accurate biomarker for Leydig cell functional capacity, reflecting their total cell number and differentiation status. Objectives: To determine the ability of INSL3 to predict hypogonadism and age-related morbidity using the EMAS cohort of older community-dwelling men. Materials & methods: Circulating INSL3 was assessed in the EMAS cohort and its cross-sectional and longitudinal relationships to hypogonadism, here defined by testosterone (T) <10.5nmol/l, and a range of age-related morbidities determined by correlation and regression analysis. Results & discussion: While INSL3 is an accurate measure of primary hypogonadism, secondary and compensated hypogonadism also indicate reduced levels of INSL3, implying that testicular hypogonadism does not improve even when LH levels are increased, and that ageing-related hypogonadism may combine both primary and secondary features. Unadjusted, serum INSL3, like calculated free testosterone (cFT), LH, or the T/LH ratio reflects hypogonadal status and is associated with reduced sexual function, bone mineral density, and physical activity, as well as increased occurrence of hypertension, cardiovascular disease, cancer, and diabetes. Using multiple regression analysis to adjust for a range of hormonal, anthropometric, and lifestyle factors, this relationship is lost for all morbidities, except for reduced bone mineral density, implying that INSL3 and/or its specific receptor, RXFP2, may be causally involved in promoting healthy bone metabolism. Elevated INSL3 also associates with hypertension and cardiovascular disease. When unadjusted, INSL3 in phase 1 of the EMAS study was assessed for its association with morbidity in phase 2 (mean 4.3 years later); INSL3 significantly predicts 7 out of 9 morbidity categories, behaving as well as cFT in this regard. In contrast, total T was predictive in only 3 of the 9 categories. Conclusion: Together with its low within-individual variance, these findings suggest that assessing INSL3 in men could offer important insight into the later development of disease in the elderly.

Indexed as

Cardiovascular DiseasesHypertensionHypogonadismAgedBiomarkersCross-Sectional StudiesHumansInsulinLeydig CellsMaleMorbidityProteinsTestosteroneBiomarkersInsulinProteinsTestosteronebone mineral densitycardiovascular diseasefrailtyhypertensionhypogonadismsexual function

Identifiers

PMID36425465
PMCPMC9679513
OpenAlexW4308461275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.